A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.

ABSTRACT:

Background

Although promising results have emerged regarding oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) for the treatment of peanut allergy (PA), direct comparisons of these approaches are limited.

Objective

This study was conducted to compare the safety, efficacy, and mechanistic correlates of peanut OIT and SLIT.

Methods

In this double-blind study children with PA were randomized to receive active SLIT/placebo OIT or active OIT/placebo SLIT. Doses were escalated to 3.7 mg/d (SLIT) or 2000 mg/d (OIT), and subjects were rechallenged after 6 and 12 months of maintenance. After unblinding, therapy was modified per protocol to offer an additional 6 months of therapy. Subjects who passed challenges at 12 or 18 months were taken off treatment for 4 weeks

SUBMITTER: Narisety SD 

PROVIDER: S-EPMC4430665 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature